Harvard Bioscience Inc.

NASDAQ: HBIO · Real-Time Price · USD
0.48
-0.05 (-9.06%)
At close: Aug 11, 2025, 3:59 PM

Harvard Bioscience Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net Income
-12.4M -3.42M -9.52M -288K
Depreciation & Amortization
7.16M 7M 7.58M 7.62M
Stock-Based Compensation
4.34M 5M 4.41M 4.17M
Other Working Capital
876K 1.71M -917K 505K
Other Non-Cash Items
1.92M 509K -3.62M 280K
Deferred Income Tax
363K 336K -414K -330K
Change in Working Capital
65K 4.6M 2.72M -10.19M
Operating Cash Flow
1.44M 14.03M 1.15M 1.26M
Capital Expenditures
-2.64M -2.31M -1.59M -1.34M
Cash Acquisitions
n/a 512K n/a n/a
Purchase of Investments
n/a n/a n/a n/a
Sales Maturities Of Investments
1.92M n/a n/a n/a
Other Investing Acitivies
-619K -523K n/a -150K
Investing Cash Flow
-1.34M -1.8M -1.59M -1.34M
Debt Repayment
227K -10.54M -1.79M 50K
Common Stock Repurchased
n/a n/a -1.63M -3.51M
Dividend Paid
n/a n/a n/a n/a
Other Financial Acitivies
-358K -2.52M 577K -302K
Financial Cash Flow
-131K -12.13M -2.84M -252K
Net Cash Flow
-175K -225K -3.31M -496K
Free Cash Flow
-1.2M 11.72M -438K -83K